New CNS-Focused Biotech Cerevance Launches With Takeda Backing

 
• By Lucie Ellis-Taitt
Human anatomy
Cerevance will focus on its portfolio of early-stage CNS compounds, including some Takeda assets • Source: Shutterstock

More from Deals

More from Business